SEC filings and other documents

ATH434 demonstrated significant efficacy and safety in MSA, advancing to Phase 3 trials.

ATH434 advances toward Phase 3 with strong cash reserves and positive clinical data.

ATH434 slowed MSA progression by up to 48% in phase II, supporting a pivotal phase III trial in 2026.

ATH434 slowed MSA progression in phase II, with global phase III and $2.4B peak sales projected.

Revenue up 717% and net loss widened 34% as ATH434 advanced toward Phase 3 for MSA.

ATH434's Phase 2 success and A$54.56M cash position set the stage for Phase 3 and global growth.

ATH-434 slowed MSA decline in phase II, with phase III and FDA engagement set for next year.

Biotech showcase featured strong investor interest and promising Phase II results for MSA therapy.

ATH434 showed strong Phase 2 efficacy in MSA, narrowing losses and boosting cash reserves.

ATH434 showed significant efficacy and safety in Phase 2 MSA trials, supporting further development.

FDA Fast Track, strong Phase 2 data, and robust cash position drive ATH434's MSA program.

ATH434 Phase 2 success and major capital raise position Alterity for accelerated MSA development.

Net loss widened to A$7.17M as ATH434 advanced in MSA trials and A$42M was raised post-period.

ATH434 slowed MSA progression and improved key outcomes in a robust, well-tolerated phase II trial.

ATH434 shows promise as a first disease-modifying therapy for Multiple System Atrophy.

ATH434 trials show promise in MSA, with strong cash reserves and key data due in 2025.

Net loss widened to A$19.1M as R&D spending rose; cash reserves at A$12.6M, equity raise planned.

ATH434-202 interim results and strong cash position highlight clinical and financial momentum.

ATH434 improved daily living in 43% of advanced MSA patients, with strong biomarker support.